首次在人中證實(shí)內(nèi)皮素直接介導(dǎo)利鈉利尿作用
發(fā)布時(shí)間:2018-10-04 20:22
【摘要】:正內(nèi)皮素受體拮抗劑是慢性腎臟病及難治性高血壓新的潛在治療藥物,但可導(dǎo)致鈉水潴留。動(dòng)物研究發(fā)現(xiàn),此副作用是由于腎小管內(nèi)皮素B受體阻滯所致。該研究的目的是通過給予亞升壓劑量的內(nèi)皮素1前體,即大內(nèi)皮素1,探討人腎小管內(nèi)皮素信號(hào)在鹽轉(zhuǎn)運(yùn)中的作用。在10個(gè)健康志愿者中進(jìn)行一項(xiàng)二期隨機(jī)、雙盲、安慰劑對(duì)照交叉試驗(yàn)。限鹽后靜脈給予研究對(duì)
[Abstract]:Positive endothelin receptor antagonist is a new potential therapy for chronic kidney disease and refractory hypertension, but it can lead to sodium retention. Animal studies have found that this side effect is due to tubular endothelin B receptor block. The aim of this study was to investigate the role of human renal tubular endothelin signal in salt transport by subpressor dose of endothelin 1 precursor, large endothelin 1. A two-phase randomized, double blind, placebo-controlled cross-control trial was conducted in 10 healthy volunteers. Study of intravenous administration after salt limitation
【分類號(hào)】:R969
[Abstract]:Positive endothelin receptor antagonist is a new potential therapy for chronic kidney disease and refractory hypertension, but it can lead to sodium retention. Animal studies have found that this side effect is due to tubular endothelin B receptor block. The aim of this study was to investigate the role of human renal tubular endothelin signal in salt transport by subpressor dose of endothelin 1 precursor, large endothelin 1. A two-phase randomized, double blind, placebo-controlled cross-control trial was conducted in 10 healthy volunteers. Study of intravenous administration after salt limitation
【分類號(hào)】:R969
【相似文獻(xiàn)】
相關(guān)期刊論文 前8條
1 唐德q,
本文編號(hào):2251753
本文鏈接:http://sikaile.net/yixuelunwen/yiyaoxuelunwen/2251753.html
最近更新
教材專著